Cargando…
Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer
AIM: The estrogen receptor coactivator Amplified in Breast Cancer 1 (AIB1) has been associated with an improved response to adjuvant tamoxifen in breast cancer, but also with endocrine treatment resistance. We hereby use metachronous contralateral breast cancer (CBC) developed despite prior adjuvant...
Autores principales: | Alkner, Sara, Bendahl, Pär-Ola, Ehinger, Anna, Lövgren, Kristina, Rydén, Lisa, Fernö, Mårten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784945/ https://www.ncbi.nlm.nih.gov/pubmed/26959415 http://dx.doi.org/10.1371/journal.pone.0150977 |
Ejemplares similares
-
Prediction of outcome after diagnosis of metachronous contralateral breast cancer
por: Alkner, Sara, et al.
Publicado: (2011) -
The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
por: Narbe, Ulrik, et al.
Publicado: (2019) -
Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer
por: Tutzauer, Julia, et al.
Publicado: (2020) -
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
por: Alkner, S., et al.
Publicado: (2017) -
Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer
por: Jögi, Annika, et al.
Publicado: (2019)